13F-HR filed by TCG Crossover Management, LLC
TCG Crossover Management, LLC filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-14, with 21 holding rows worth $566,607,730.
- Accession
- 0001214659-23-002234
- Filer
- CIK 1839948
- Filed
- 2023-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2022
A holdings report, 21 entries on the cover page, a total value of $566,607,730 stated on the cover page (in dollars after the unit check, H1), rows summing to $566,607,730 with VALUE read as dollars as filed, 13F file number 028-22283. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| IVERIC BIO INC | 46583P102 | COM | 5,141,118 | $110,071,336 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 288,054 | $83,607,674 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 3,631,042 | $41,974,846 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 5,905,400 | $37,026,858 | dollars as filed | |
| GERON CORP | 374163103 | COM | 15,187,073 | $36,752,717 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 2,104,875 | $32,099,344 | dollars as filed | |
| AEROVATE THERAPEUTICS INC | 008064107 | COM | 1,081,274 | $31,681,328 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 983,610 | $28,731,248 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 787,231 | $25,813,304 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 3,395,495 | $22,953,546 | dollars as filed | |
| VECTIVBIO HLDG AG | H9060V101 | COM | 2,333,300 | $20,218,045 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 1,144,939 | $18,032,789 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 1,423,642 | $17,667,397 | dollars as filed | |
| IMMUNOVANT INC | 45258J102 | COM | 854,853 | $15,173,641 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 1,989,103 | $15,117,183 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 1,000,000 | $10,500,000 | dollars as filed | |
| ENTRADA THERAPEUTICS INC COM | 29384C108 | Stock | 584,955 | $7,908,592 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 300,000 | $4,641,000 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 486,795 | $4,502,854 | dollars as filed | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 253,069 | $1,860,057 | dollars as filed | |
| ELEVATION ONCOLOGY INC COM | 28623U101 | Stock | 288,390 | $273,971 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-23-002234 | this filing | 2023-02-14 | acceptance time not in the bulk data set |